The Beauty Health Company (SKIN) Stock Forecast
SKIN analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 9 analysts
- Price target
- $18.17 average of analyst targets
- Upside to target
- +72.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.27
- 52-week range
- $10.50 – $31.80
SKIN analyst ratings
9 analystsNumber of analysts at each rating.
SKIN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SKIN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.57 | −100.0% | 1 |
| Current fiscal year (2026) | $2.56 | $2.56 | $2.56 | $6.80 | −62.4% | 1 |
| Next fiscal year (2027) | $3.82 | $3.82 | $3.82 | $2.56 | +49.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SKIN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $67.9M | $66.4M | $70.0M | −3.9% | 8 |
| Current fiscal year (2026) | $285.1M | $282.2M | $287.4M | −5.2% | 9 |
| Next fiscal year (2027) | $299.1M | $285.7M | $325.9M | +4.9% | 9 |
SKIN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SKIN revenue: reported and forecast
SKIN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | 0 up · 0 down |
| Current fiscal year (2026) | $2.20 | $0.00 | $2.60 | $2.60 | $2.56 | +16.4% | 1 up · 0 down |
| Next fiscal year (2027) | $3.00 | $3.00 | $3.80 | $3.80 | $3.82 | +27.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SKIN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SKIN beat in 10 of 12.
What analysts expect from SKIN
9 analysts cover Beauty Health; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.17, 72.0% above the latest close of $10.56. Analysts expect earnings of $2.56 per share for 2026, −62.4% from a year earlier. For 2027 the average estimate is $3.82 per share on revenue of $299.1 million. Beauty Health beat the EPS estimate in 10 of the last 12 quarters.
Related: SKIN income statement, SKIN key metrics, SKIN chart. See the SKIN stock overview for the latest quote and news.
SKIN forecast FAQ
What is Beauty Health's price target?
The average analyst price target for Beauty Health is $18.17, 72.0% above the latest close of $10.56.
Is Beauty Health a buy, hold or sell?
Of 9 analysts covering Beauty Health, 1 rate it a strong buy, 0 a buy, 6 a hold, 2 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Beauty Health's EPS forecast?
Analysts forecast $2.56 per share for 2026 (range $2.56 to $2.56); for 2027 the estimate is $3.82.
What is Beauty Health's revenue forecast?
The average revenue estimate for 2026 is $285.1 million, growth of −5.2%; for 2027 it is $299.1 million.
When does Beauty Health report earnings?
Beauty Health is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-1.27.
Does Beauty Health usually beat earnings estimates?
Beauty Health reported EPS at or above the analyst estimate in 10 of the last 12 quarters.